Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s President and Chief Executive Officer, Mark Pruzanski, sold 10,000 shares of Common Stock on Tuesday, exercising a stock option pursuant to a Rule 10b5-1 plan. The shares were sold directly, for a price of $250.61 per share. Furthermore, the disposition was the second to be executed by Pruzanski during Q1, as he unloaded 10,000 shares of Common Stock in the beginning of June, paying $230.60 per share. The insider’s company holdings currently amount to a total of 475,042.
Intercept’s Chief Marketing Officer and Executive Vice President, David Shapiro, also completed a disposition on Wednesday, through which the insider sold 5,036 shares of Common Stock at an average price of $244.75 per share. The Executive VP, much like Pruzanski, has consistently been unloading shares of the $5.18 billion market cap biopharmaceutical firm this quarter, although in much smaller volume than his fellow insider.
In terms of quarterly hedge fund movements, there’s a new shareholder position, occupied by Andreas Halvorsen’s Viking Global, which now owns 454,917 shares, with a value of $150 million.
Disclosure: none
